ACE and hepatocellular carcinoma: Jun Ji et al. have also demonstrated that DCP can be used in identifying AFP-negative HCC, and has improved performance in HCC surveillance, early diagnosis, treatment response, and recurrence monitoring in the HBV-related population [76].